Single Gene Mutation Reveals Why Throat Cancers Come Back After Cisplatin Success

In one of the more sobering patterns in oncology, patients with hypopharyngeal squamous cell carcinoma often respond beautifully to induction chemotherapy, their tumors shrinking dramatically or disappearing entirely on initial scans, only for the disease to return months later in a form that no longer answers to the same drugs. A new study published in the British Journal of Cancer by a team at Fudan University in Shanghai now offers a molecular explanation for this cruel arc of initial triumph and eventual relapse. By sequencing the genomes of tumors taken before treatment and again after progression, the researchers traced recurrence to mutations that were absent in the original tumor but emerged under the pressure of therapy. Among these newly acquired genetic alterations, one gene stood out: ENPP1, an enzyme with a growing reputation as a master regulator of both chemotherapy response and immune signaling in cancer.

The clinical backdrop makes the finding consequential. Hypopharyngeal squamous cell carcinoma, which arises in the region of the throat surrounding the larynx, is among the most lethal head and neck malignancies, with survival rates that have remained stubbornly poor for decades. Induction chemotherapy, typically built around the platinum drug cisplatin, is a cornerstone of treatment because it can shrink tumors enough to permit organ-preserving surgery or definitive radiation. Yet the strategy carries an inherent gamble: if resistance develops, the window for effective intervention narrows dramatically. Understanding why some tumors evolve resistance while others remain sensitive has therefore been a central question, and the mechanisms of acquired resistance to induction chemotherapy in this disease had remained incompletely mapped until now.

To interrogate that question at the genomic level, the team turned to a rare and valuable resource: paired tissue samples from nine patients with hypopharyngeal squamous cell carcinoma who had shown an initial complete or strong response to induction chemotherapy and then progressed. Because the archived paraffin-embedded specimens from both time points were available, the researchers could perform whole exome sequencing on the pre-treatment tumor and its recurrent descendant from the same patient, effectively watching tumor evolution in action. The comparison revealed that two-thirds of the patients, six of the nine, had acquired novel mutations during progression that were not detectable in their original tumors. This pattern of newly emerged variants is the genomic fingerprint of Darwinian selection, in which therapy eliminates susceptible cells and spares those rare clones carrying mutations that confer a survival advantage.

Among the newly emerged alterations, changes in three genes drew particular attention for their potential functional relevance: ENPP1, ALK, and ATP10B. But it was ENPP1 that dominated the analysis. Mutations in this gene were present in half of the six patients who had acquired new variants during progression, a striking enrichment for a single gene in so small a cohort. ENPP1 encodes ectonucleotide pyrophosphatase/phosphodiesterase 1, a membrane-bound enzyme best known in cancer biology for its ability to degrade 2’3′-cGAMP, the small signaling molecule that activates the STING pathway, a critical arm of innate immune sensing. Previous work in breast cancer and other tumor types had already implicated ENPP1 as a kind of innate immune checkpoint, allowing tumors to dampen the cGAS-STING alarm system that would otherwise flag them for immune destruction.

To move from correlation to causation, the researchers built a functional toolkit in the laboratory. Using CRISPR-Cas9-mediated knockout, they deleted ENPP1 from hypopharyngeal cancer cells and observed that its loss suppressed the malignant phenotypes that define aggressive disease, including proliferative capacity and survival under stress. Conversely, when they introduced the specific mutant variant found in the patients, a single nucleotide change designated c.2596 G > C that swaps a glutamine for a glutamic acid at position 866 of the protein, the effect reversed dramatically. Cells engineered to express mutant ENPP1 became markedly more resistant to cisplatin, the workhorse drug of induction regimens. The mutation also enhanced the enzyme’s hydrolysis of 2’3′-cGAMP, meaning the mutant protein was not merely a passive passenger but an actively more capable destroyer of the immune-activating messenger molecule.

The mechanistic thread connecting these observations runs through the STING pathway, and the study’s findings here are notable for their apparent paradox. Rather than simply shutting STING down, ENPP1 mutation was associated with sustained activation of STING, accompanied by enhanced signaling through the transcription factor NF-κB and elevated production of interleukin-6, a pro-inflammatory cytokine with well-documented roles in tumor cell survival. This matters because STING is a double-edged sword in cancer immunology. In one context, its activation recruits immune cells and sensitizes tumors to immunotherapy; in another, chronic STING engagement drives NF-κB and IL-6 signaling that promotes survival of genomically unstable cancer cells, a phenomenon documented in prior studies of chromosomally unstable cancers and triple-negative breast cancer. The Fudan team’s data suggest that in hypopharyngeal carcinoma, the mutant enzyme tilts STING signaling toward the pro-survival, inflammatory branch rather than the anti-tumor interferon response.

The in vivo evidence strengthened the case considerably. When the researchers tested the mutant ENPP1 in xenograft models, transplanting engineered tumor cells into mice, the mutation increased tumorigenic capacity, meaning tumors carrying the mutant gene grew more aggressively. Critically, those xenografts also displayed resistance to cisplatin treatment, confirming that the mutation’s effects were not artifacts of cell culture but translated into treatment failure in living tissue. Together, the in vitro and in vivo experiments establish ENPP1 mutation as a functional driver of both enhanced malignancy and chemotherapy resistance, satisfying the criteria that molecular oncologists typically demand before accepting a gene as a genuine therapeutic target rather than a bystander in tumor evolution.

The implications extend beyond cisplatin resistance into the realm of immunotherapy and treatment sequencing. Because ENPP1 mutations mediate what the authors describe as both chemotherapy resistance and immunomodulation, the finding suggests that recurrent tumors carrying these alterations may exist in a distinctly different immune microenvironment than their treatment-naive ancestors. If mutant ENPP1 reshapes STING signaling and IL-6 production, it could influence how recurrent hypopharyngeal cancers respond to immune checkpoint inhibitors, which are increasingly used in head and neck cancer. It also raises the prospect of therapeutic intervention at the ENPP1 enzyme itself; small-molecule ENPP1 inhibitors are under active development in other tumor contexts, and this study provides a rationale for evaluating them in hypopharyngeal carcinoma, potentially in combination with platinum chemotherapy to prevent or delay the emergence of resistant clones.

Caveats remain, as they must in any study of this scale. Nine patients is a small cohort, and the retrospective design means the findings require validation in larger, prospective series before ENPP1 mutation testing could enter clinical decision-making. The data underlying the study are not publicly available due to privacy and ethical considerations but can be obtained from the corresponding authors upon reasonable request, and the work was approved by the ethics committee of the Eye and ENT Hospital of Fudan University with informed consent from all participants. Still, the study’s central contribution is conceptual as much as practical: it demonstrates that the seeds of relapse are written in the genome during treatment, and it names a specific, druggable culprit. For patients whose tumors vanish on scan only to return with lethal defiance, that molecular clarity is the first step toward intercepting resistance before it takes hold.

Subject of Research: ENPP1 mutation-driven cisplatin resistance through the STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma

Article Title: From initial complete response to recurrence: ENPP1 mutation drives cisplatin resistance through STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma

Article References: Hu, C., Liu, X., Yuan, C., Zhang, L., Yang, R., Liu, R., Xiang, W., Yang, R., Hu, Q., Yu, M., Chen, J., Huang, Q., Ma, D., & Zhang, J. (2026). From initial complete response to recurrence: ENPP1 mutation drives cisplatin resistance through STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03625-5

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03625-5

Keywords: ENPP1, cisplatin resistance, hypopharyngeal squamous cell carcinoma, STING pathway, NF-κB, IL-6, whole exome sequencing, tumor recurrence, induction chemotherapy, cGAMP, head and neck cancer, CRISPR-Cas9